S

Sage Therapeutics

D
SAGE
USD
0.385
(6.4815%)
Market Closed
24,778.00
Volume
-6.35
EPS
-
Div Yield
-0.853576
P/E
386,143,893.85
Market Cap
Today
6.4815%
1 Week
3.944%
1 Month
-5.878%
6 Months
-51.234%
12 Months
-67.746%
Year To Date
-70.772%
All Time
0%

Title:
Sage Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Do you need help or have a question?